用于评估囊性纤维化跨膜传导调节因子（CFTR）离子通道活性的鼻电位差测量
Nasal potential difference measurements to assess CFTR ion channel activity.
作者信息
Rowe Steven M, Clancy John Paul, Wilschanski Michael
机构信息
Department of Medicine, University of Alabama, Birmingham, AL 35294-0006, USA.
出版信息
Methods Mol Biol. 2011;741:69-86. doi: 10.1007/978-1-61779-117-8_6.
Abstract
The Nasal potential difference measurement is used to measure the voltage across the nasal epithelium, which results from transepithelial ion transport and reflects in part CFTR function. The electrophysiologic abnormality in cystic fibrosis was first described 30 years ago and correlates with features of the CF phenotype. NPD measurement is an important in vivo research and diagnostic tool, and is used to assess the efficacy of new treatments such as gene therapy and ion transport modulators. This chapter will elaborate on the electrophysiological principles behind the test, the equipment required, the methods, and the analysis of the data.
摘要
鼻电位差测量用于测量鼻上皮细胞两端的电压，该电压由跨上皮离子转运产生，部分反映了囊性纤维化跨膜传导调节因子（CFTR）的功能。囊性纤维化的电生理异常在30年前首次被描述，与CF表型的特征相关。鼻电位差测量是一种重要的体内研究和诊断工具，用于评估基因治疗和离子转运调节剂等新治疗方法的疗效。本章将详细阐述该测试背后的电生理原理、所需设备、方法以及数据分析。
相似文献
1
Nasal potential difference measurements to assess CFTR ion channel activity.用于评估囊性纤维化跨膜传导调节因子（CFTR）离子通道活性的鼻电位差测量
Methods Mol Biol. 2011;741:69-86. doi: 10.1007/978-1-61779-117-8_6.
2
Basic protocol for transepithelial nasal potential difference measurements.经上皮鼻腔电位差测量的基本方案。
J Cyst Fibros. 2004 Aug;3 Suppl 2:151-5. doi: 10.1016/j.jcf.2004.05.032.
3
Transepithelial nasal potential difference (NPD) measurements in cystic fibrosis (CF).囊性纤维化（CF）患者的经上皮鼻腔电位差（NPD）测量
Med Wieku Rozwoj. 2013 Jan-Mar;17(1):13-7.
4
In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis.体内鼻电位差：评估囊性纤维化基因转移疗效的技术与方案
Hum Gene Ther. 1995 Apr;6(4):445-55. doi: 10.1089/hum.1995.6.4-445.
5
The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.CF-CIRC研究：一项法国合作研究，旨在评估新生儿筛查中囊性纤维化诊断的准确性。
BMC Pediatr. 2006 Oct 3;6:25. doi: 10.1186/1471-2431-6-25.
6
Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis.人鼻腔上皮的顶端 CFTR 表达与囊性纤维化的肺部疾病相关。
PLoS One. 2013;8(3):e57617. doi: 10.1371/journal.pone.0057617. Epub 2013 Mar 6.
7
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).鼻黏膜跨上皮电位差（NPD）的标准化测量
J Vis Exp. 2018 Sep 13(139):57006. doi: 10.3791/57006.
8
A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.一项关于腺病毒载体介导的基因转移在囊性纤维化患者鼻上皮中的对照研究。
N Engl J Med. 1995 Sep 28;333(13):823-31. doi: 10.1056/NEJM199509283331302.
9
Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice.囊性纤维化跨膜电导调节因子（CFTR）敲除和 F508del-CFTR 小鼠鼻电位差的特征。
PLoS One. 2013;8(3):e57317. doi: 10.1371/journal.pone.0057317. Epub 2013 Mar 7.
10
Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?各种离子通道测量的整合是否能提高囊性纤维化的诊断性能？
Ann Am Thorac Soc. 2014 May;11(4):562-70. doi: 10.1513/AnnalsATS.201311-412OC.
引用本文的文献
1
Phytochemical-mediated efferocytosis and autophagy in inflammation control.植物化学物质介导的胞葬作用和自噬在炎症控制中的作用
Cell Death Discov. 2024 Dec 18;10(1):493. doi: 10.1038/s41420-024-02254-2.
2
Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.调节剂难治性囊性纤维化：定义一个新兴高危人群的范围和挑战。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241297877. doi: 10.1177/17534666241297877.
3
Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia.澳大利亚昆士兰州囊性纤维化患者中罕见囊性纤维化跨膜传导调节因子突变组合的表型评估
J Clin Med. 2024 Oct 18;13(20):6210. doi: 10.3390/jcm13206210.
4
Personalized CFTR Modulator Therapy for and Homozygous Patients with Cystic Fibrosis.囊性纤维化跨膜传导调节因子个体化调节剂治疗和纯合子患者。
Int J Mol Sci. 2023 Aug 2;24(15):12365. doi: 10.3390/ijms241512365.
5
Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G.ELX/TEZ/IVA对两名患有罕见CFTR剪接突变c.273+1G>A和c.165-2A>G的患者器官特异性CFTR功能的不同影响。
Front Pharmacol. 2023 Mar 27;14:1153656. doi: 10.3389/fphar.2023.1153656. eCollection 2023.
6
The Cystic Fibrosis Upper and Lower Airway Metagenome.囊性纤维化上、下呼吸道宏基因组
Microbiol Spectr. 2023 Mar 9;11(2):e0363322. doi: 10.1128/spectrum.03633-22.
7
Diagnostic agreement among experts assessing adults presenting with possible cystic fibrosis: need for improvement and implications for patient care.评估疑似囊性纤维化成年患者的专家之间的诊断一致性：改进的必要性及对患者护理的影响
ERJ Open Res. 2022 Dec 12;8(4). doi: 10.1183/23120541.00227-2022. eCollection 2022 Oct.
8
Vegetable glycerin e-cigarette aerosols cause airway inflammation and ion channel dysfunction.蔬菜甘油电子烟烟雾会导致气道炎症和离子通道功能障碍。
Front Pharmacol. 2022 Sep 26;13:1012723. doi: 10.3389/fphar.2022.1012723. eCollection 2022.
9
Assays of CFTR Function In Vitro, Ex Vivo and In Vivo.体外、离体和体内 CFTR 功能测定。
Int J Mol Sci. 2022 Jan 27;23(3):1437. doi: 10.3390/ijms23031437.
10
Assessment of Lentiviral Vector Mediated CFTR Correction in Mice Using an Improved Rapid Nasal Potential Difference Measurement Protocol.使用改进的快速鼻电位差测量方案评估慢病毒载体介导的小鼠CFTR校正。
Front Pharmacol. 2021 Jul 27;12:714452. doi: 10.3389/fphar.2021.714452. eCollection 2021.
本文引用的文献
1
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.从新生儿到老年人的囊性纤维化诊断指南：囊性纤维化基金会共识报告。
J Pediatr. 2008 Aug;153(2):S4-S14. doi: 10.1016/j.jpeds.2008.05.005.
2
Reproducibility of nasal potential difference measurements in cystic fibrosis.囊性纤维化患者鼻电位差测量的可重复性
Chest. 2007 Oct;132(4):1219-26. doi: 10.1378/chest.06-2975. Epub 2007 Sep 21.
3
Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.在早期临床试验中检测囊性纤维化跨膜传导调节因子活性
Proc Am Thorac Soc. 2007 Aug 1;4(4):387-98. doi: 10.1513/pats.200703-043BR.
4
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.静脉注射庆大霉素对囊性纤维化患者终止密码子抑制的体外预测：一项初步研究。
BMC Med. 2007 Mar 29;5:5. doi: 10.1186/1741-7015-5-5.
5
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.在患有囊性纤维化且存在终止突变的患者中，鼻用氨基糖苷类药物未使囊性纤维化跨膜传导调节因子出现可检测到的改善。
Am J Respir Cell Mol Biol. 2007 Jul;37(1):57-66. doi: 10.1165/rcmb.2006-0173OC. Epub 2007 Mar 8.
6
Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.囊性纤维化跨膜调节基因的突变与体内跨上皮电位
Am J Respir Crit Care Med. 2006 Oct 1;174(7):787-94. doi: 10.1164/rccm.200509-1377OC. Epub 2006 Jul 13.
7
Cystic fibrosis: terminology and diagnostic algorithms.囊性纤维化：术语和诊断算法
Thorax. 2006 Jul;61(7):627-35. doi: 10.1136/thx.2005.043539. Epub 2005 Dec 29.
8
Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners.囊性纤维化跨膜传导调节因子及其相互作用蛋白的大分子复合物
Pharmacol Ther. 2005 Nov;108(2):208-23. doi: 10.1016/j.pharmthera.2005.04.004. Epub 2005 Jun 2.
9
Cystic fibrosis.囊性纤维化
N Engl J Med. 2005 May 12;352(19):1992-2001. doi: 10.1056/NEJMra043184.
10
Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.给予囊性纤维化受试者鼻粘膜的致密DNA纳米颗粒是安全的，并显示出部分至完全的囊性纤维化跨膜传导调节因子重构。
Hum Gene Ther. 2004 Dec;15(12):1255-69. doi: 10.1089/hum.2004.15.1255.
Zotero 插件